title: Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
abstract: An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.
authors.affiliation: Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Bachy
authors.affiliation: Hematology Department, Concord Hospital, Concord, NSW, Australia.
authors.forename: Jane A
authors.initials: JA
authors.lastname: Estell
authors.affiliation: Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.
authors.forename: Eric
authors.initials: E
authors.lastname: Van de Neste
authors.affiliation: Hematology Department, Institut Paoli Calmettes, Marseille, France.
authors.forename: Réda
authors.initials: R
authors.lastname: Bouabdallah
authors.affiliation: Hematology Department, Hospital Son Llàtzer, Palma De Mallorca, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Bargay
authors.affiliation: Hematology Department, CHU De Reims, Reims, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Delmer
authors.affiliation: Deparment of Biostatistics, Lysarc, Lyon, France.
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Gelas-Dore
authors.affiliation: Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.
authors.forename: Maria
authors.initials: M
authors.lastname: Gomes da Silva
authors.affiliation: Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Fitoussi
authors.affiliation: Hematology Department, University Hospital Hradec Kràlové, Prague, Czech Republic.
authors.forename: David
authors.initials: D
authors.lastname: Belada
authors.affiliation: Hematology Department, Centre Hospitalier De La Roche Sur Yon, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Maisonneuve
authors.affiliation: Hematology Department, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Tanin
authors.initials: T
authors.lastname: Intragumtornchai
authors.affiliation: Hematology Department, Centre Hospitalier Pontchaillou, Rennes, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Lamy
authors.affiliation: Hematology Department, Institut Gustave Roussy, Villejuif, France.
authors.forename: Peggy
authors.initials: P
authors.lastname: Dartigues
authors.affiliation: Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
authors.forename: John Francis
authors.initials: JF
authors.lastname: Seymour
authors.affiliation: Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D004347:Drug Interactions; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors